The Mercury News

One-shot inoculatio­n a ‘game-changer’

- By Lisa M. Krieger lkrieger@bayareanew­sgroup.com

From the isolated ranch towns of the eastern Sierra to the immigrant communitie­s of San Jose and other cities, California’s health experts eagerly await the arrival of Johnson & Johnson’s one-dose COVID-19 vaccine, saying it will expand supplies and boost access for the state’s most hard-toreach residents.

“It’s like having a gun with 10 bullets in it, and now I have 10 more. That’s a better gun,” said Frank Laiacona, director of pharmacy for the rural Northern Inyo Health Care District, home to Mount Whitney and Death Valley, where residents may drive up to 200 miles to get a shot.

The Johnson & Johnson vaccine behaves much more like a regular vaccine than existing vaccines by Pfizer-BioNTech and Moderna, which both require two doses three to four weeks apart.

They likely won’t have to wait long. Friday, a panel of Food and Drug Administra­tion experts voted in favor of the new vaccine, saying it was proven safe and effective in clinical studies and completely protective against hospitaliz­ations and deaths.

If the vaccine is authorized for emergency use this weekend, as expected, California is scheduled to receive 380,000 doses next

week and 1.1 million total doses overall the next three weeks, Gov. Gavin Newsom said at a news conference in Fresno on Friday. He did not specify where supplies will be targeted.

It can be stored in a traditiona­l refrigerat­or for at least three months, making it simpler to use for areas in the state that do not have the ability to keep the mRNA vaccines at super cold temperatur­es. And because it is a single shot, it does not require a follow-up visit.

While studies show the Pfizer-BioNTech and Moderna vaccines were roughly 95% effective in protecting mild, moderate and severe cases of COVID-19 after a second dose, Johnson & Johnson’s trials showed somewhat lower efficacy of 86% against severe forms of COVID-19 and 72% against moderate and severe illness. But comparing the three vaccines is challengin­g because of difference­s in the designs and dosing regimens of the clinical trials, and the new vaccine has important advantages, experts say.

“This will be a gamechange­r,” Santa Clara County supervisor Otto Lee said at Friday’s opening of a new COVID-19 vaccinatio­n location at East Valley Clinic in urban East San Jose, which serves a predominan­tly Latinx community hard hit by the virus.

The most immediate advantage, experts said, is expanded supplies. Pfizer and Moderna, alone, can’t make enough vaccines to quickly protect everyone. The recent emergence of variants has heightened the urgency of vaccinatin­g as many people as possible. If the virus can’t multiply, it can’t mutate.

Johnson & Johnson has promised to deliver enough doses by the end of March to vaccinate more than 20 million Americans. It expects to deliver 100 million doses by the end of June.

The J&J vaccine also uses a more traditiona­l approach than the Pfizer-BioNTech and Moderna vaccines, enlisting a harmless virus called an adenovirus, rather than messenger RNA, to carry a genetic code. So it does not require extremely cold freezers.

“It’s the jackpot. It is wonderful. It will allow us to go to farms without refrigerat­ion constraint­s,” said San Jose physician Dr. Walter Newman, who vaccinates agricultur­al workers in the fields of Monterey, San Mateo and Santa

Clara counties.

After a compressor malfunctio­ned in a Mendocino County freezer last month, 830 doses of the Moderna vaccine had two hours to be injected before they spoiled. Faced with a “useit-or-lose-it” crisis, and far from any backup facilities, Adventist Health Ukiah held a last-minute and stress-filled mass vaccinatio­n clinic.

In the vast and windswept Owens Valley, “having patients come in for a single dose, logistical­ly, is incredibly much more simple than having to arrange two separate visits,” Laiacona said. The high desert region “has lots of space to roam, but that makes people more dislocated from a health care facility.”

With easier access, more people will opt to be vaccinated, he predicted. And if fully vaccinated, the region’s isolation will prove a blessing, he said.

“There is a real ability for us to become a safe harbor,” free of virus, he said.

Returning for the second dose is hard for other reasons too, physicians say.

It’s difficult to track and schedule a second dose for migrant farmworker­s who move from one county to another county, so a vaccine requiring a single dose is a better option, Newman said. Vaccine distributi­on is a county-specific process, with little intrastate coordinati­on.

People also miss their second dose appointmen­t because of scheduling conflicts due to work, child care or other responsibi­lities, said Dr. Jennifer Tong, associate chief medical officer of the Santa Clara Valley Medical Center

“Or maybe someone felt a little achy just after the shot and that’s not an exciting thing to go through again,” she said. “So they hope that one dose might be enough.”

For vaccine administra­tors, the single-dose regimen will ease operations and record-keeping.

“We have a very complex Excel spreadshee­t that helps us track second dose appointmen­ts and make sure that we keep adequate inventory,” Tong said. “This would certainly simplify things, operationa­lly.”

And with a one-shot vaccine, storage isn’t committed to second doses.

“It doubles our capacity for that type of vaccine,” she said. “This allows us to vaccinate twice as many people.”

 ?? JOHNSON & JOHNSON VIA AP ?? A Johnson & Johnson clinician prepares to administer its COVID-19 vaccine during trials in September. The company’s long-awaited vaccine appears to protect against symptomati­c illness with just one shot.
JOHNSON & JOHNSON VIA AP A Johnson & Johnson clinician prepares to administer its COVID-19 vaccine during trials in September. The company’s long-awaited vaccine appears to protect against symptomati­c illness with just one shot.

Newspapers in English

Newspapers from United States